Abstract 371P
Background
Hypertension is widely recognized as a significant risk factor for urologic tumors, encompassing malignancies of the prostate, kidney, bladder, and testes. However, the impact of antihypertensive drugs on urologic tumors remains ambiguous.
Methods
We performed a Mendelian randomization (MR) analysis to assess the influence of antihypertensive drugs on urologic tumors. We employed two-sample MR and Summary data-based Mendelian randomization (SMR) to thoroughly examine the impact of antihypertensive drug target genes on urologic tumors. Utilizing a mediated MR, we further investigated the mediating effects of proteomics in the relationship between the target genes and urologic tumors. Furthermore, MR was integrated into the Phenome-Wide Association Study (PheWAS) framework to investigate the correlation between antihypertensive drug targets and clinical diagnoses.
Results
Study demonstrated the impact of various antihypertensive drugs on urologic tumors, with calcium channel blockers (CCBs) and Vasodilator antihypertensives identified as potential risk factors for all urologic tumors. Furthermore, cross-validation analysis indicates that PPARG serves as a risk factor for testicular cancer (SMR: P = 0.02, OR = 1.9, and 95%CI: 1.1-3.3; TSMR: P = 3.2E-10-2, OR = 1.4, and 95%CI: 1.1-1.8;), whereas CACNA1H functions as a protective factor against kidney cancer(SMR: P = 0.04, OR = 0.75, and 95%CI: 0.57-0.99; TSMR: P = 3.2E-10-2, OR = 0.95, and 95%CI: 0.91-0.99;), and ACE confers protection against prostate cancer(SMR: P = 0.04, OR = 0.79, and 95%CI: 0.63-0.99; TSMR: P = 1.9E-10-15, OR = 0.93, and 95%CI: 0.91-0.95;). Several proteins have been identified as mediators of the association between antihypertensive drug targets and urologic tumors, with TYMP exhibiting the highest frequency.
Conclusions
Patients with urologic tumors should be careful when using certain CCBs and Vasodilator antihypertensives. Moreover, the connection between targets of antihypertensive drugs and urologic tumors has been elucidated through changes in blood protein levels, offering valuable insights that may inform the treatment and prevention strategies for urologic tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.